Bolt Biotherapeutics IPO

Bolt Biotherapeutics is a biotechnology company developing Boltbody™ Immune-stimulating Antibody Conjugates (ISAC), a new class of immuno-oncology therapeutics that have eliminated tumors following systemic administration in preclinical studies and results in the development of immunological memory, which may lead to more durable clinical responses for patients.

Register for Details

For more details on financing and valuation for Bolt Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

What is Bolt Biotherapeutics's ticker symbol?


What is Bolt Biotherapeutics's stock price?

1.04 as of 9/22/23

Learn more about Bolt Biotherapeutics

Forge green plus iconForge green minus icon

What is Bolt Biotherapeutics funding to date?

Bolt Biotherapeutics has raised $64.6MM to date.
Forge green plus iconForge green minus icon

When was Bolt Biotherapeutics founded?

Bolt Biotherapeutics was founded in 2015.
Updated on: Jun 12, 2022